{"doi":"10.1056/oh201005250000001","title":"Unknown","abstract":null,"journal":null,"year":null,"id":626846,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Costs of Treatment: Fracture Prevention in Men Who Receive Androgen-Deprivation Therapy","abstract":"Accelerated bone loss related to androgen-deprivation therapy (ADT) is a potential problem among men with prostate cancer. Because most of these men receive ADT in the nonmetastatic setting, therapy can be prolonged, thereby raising risk for bone-related morbidity. A number of antiresorptive agents can mitigate ADT-related bone loss, but no agents currently are indicated to lower fracture rates among men in this setting. Moreover, no uniform guidelines exist for monitoring or managing ADT-related bone complications, and the costs and potential side …","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W2566723029","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.34572675,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.jwatch.org/oh201005250000001/2010/05/25/costs-treatment-fracture-prevention-men-who","host_type":"journal"}],"fields_of_study":["Bone health and treatments","Prostate Cancer Treatment and Research","Bone health and osteoporosis research","Medicine"],"mesh_terms":[],"keywords":["Androgen deprivation therapy","Medicine","Prostate cancer","Oncology","Internal medicine","Intensive care medicine","Physical therapy","Cancer"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T15:25:10.096725Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}